Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is a promising company with a positive outlook as their pipeline includes several small molecule products targeting chronic inflammatory and autoimmune diseases. The Phase 3 ENSURE program in RMS for vidofludimus calcium has shown positive results and a reduction in new MRI lesions, indicating potential benefits in terms of relapse and progression reduction. Additionally, vidofludimus calcium offers a unique dual-mechanism of both Nurr1 activation for disease modification and DHODH inhibition for anti-inflammatory effects. However, there may be questions surrounding the long-term impact and efficacy of these treatments.

Bears say

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases. While they are focused on promising therapies, the lack of diversification in their Life Science segment and the potential for the underlying diseases they are targeting to have alternative treatment options causes concern for the success of their lead candidate, vidofludimus calcium, in treating multiple sclerosis. Additionally, the company's financials and projected peak market share may not support its current stock price.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.